BACKGROUND AND AIMS: Automated chyme reinfusion (CR) in patients with intestinal failure (IF) and a temporary double enterostomy (TDE) restores intestinal function and protects against liver injury, but the mechanisms are incompletely understood. The aim was to investigate whether the beneficial effects of CR relate to functional recovery of enterohepatic signaling through the bile salt-FGF19 axis. APPROACH AND RESULTS: Blood samples were collected from 12 patients, 3 days before, at start, and 1, 3, 5, and 7 weeks after CR initiation. Plasma FGF19, total bile salts (TBS), 7-α-hydroxy-4-cholesten-3-one (C4; a marker of bile salt synthesis), citrulline (CIT), bile salt composition, liver tests, and nutritional risk indices were determined. Paired small bowel biopsies prior to CR and after 21 days were taken, and genes related to bile salt homeostasis and enterocyte function were assessed. CR induced an increase in plasma FGF19 and decreased C4 levels, indicating restored regulation of bile salt synthesis through endocrine FGF19 action. TBS remained unaltered during CR. Intestinal farnesoid X receptor was up-regulated after 21 days of CR. Secondary and deconjugated bile salt fractions were increased after CR, reflecting restored microbial metabolism of host bile salts. Furthermore, CIT and albumin levels gradually rose after CR, while abnormal serum liver tests normalized after CR, indicating restored intestinal function, improved nutritional status, and amelioration of liver injury. CR increased gene transcripts related to enterocyte number, carbohydrate handling, and bile salt homeostasis. Finally, the reciprocal FGF19/C4 response after 7 days predicted the plasma CIT time course. CONCLUSIONS: CR in patients with IF-TDE restored bile salt-FGF19 signaling and improved gut-liver function. Beneficial effects of CR are partly mediated by recovery of the bile salt-FGF19 axis and subsequent homeostatic regulation of bile salt synthesis.

Department of Clinical Epidemiology and Medical Technology Assessment Maastricht University Medical Center Maastricht the Netherlands

Department of General Visceral and Transplantation Surgery RWTH University Hospital Aachen Aachen Germany

Department of Nutritional and Digestive Rehabilitation Clinique Saint Yves Rennes France

Department of Surgery Maastricht University Medical Center Maastricht the Netherlands

INSERM INRAE University of Rennes Nutrition Metabolisms and Cancer NuMeCan Nutrition Unit CRB Santé CHU Rennes Rennes France

Institute of Medical Biochemistry and Laboratory Diagnostics 1st Faculty of Medicine Charles University Prague Czech Republic

NUTRIM School of Nutrition and Translational Research in Metabolism Maastricht University Maastricht the Netherlands

Zobrazit více v PubMed

Pironi L, Arends J, Baxter J, Bozzetti F, Peláez RB, Cuerda C, et al. ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults. Clin Nutr 2015;34:171‐180. PubMed

Oterdoom LH, ten Dam SM, de Groot SDW, Arjaans W, van Bodegraven AA, et al. Limited long‐term survival after in‐hospital intestinal failure requiring total parenteral nutrition. Am J Clin Nutr 2014;100:1102‐1107. PubMed

Burden S, Hemstock M, Taylor M, Teubner A, Roskell N, MacCulloch A, et al. The impact of home parenteral nutrition on the burden of disease including morbidity, mortality and rate of hospitalisations. Clin Nutr ESPEN 2018;28:222‐227. PubMed

Rinsema W, Gouma DJ, von Meyenfeldt MF, Soeters PB. Reinfusion of secretions from high‐output proximal stomas or fistulas. Surg Gynecol Obstet 1988;167:372‐376. PubMed

Lévy É, Palmer DL, Frileux P, Parc R, Huguet C, Loygue J, et al. Inhibition of upper gastrointestinal secretions by reinfusion of Succus entericus into the distal small bowel. A clinical study of 30 patients with peritonitis and temporary enterostomy. Ann Surg 1983;198:596‐600. PubMed PMC

Picot D, Garin L, Trivin F, Kossovsky MP, Darmaun D, Thibault R, et al. Plasma citrulline is a marker of absorptive small bowel length in patients with transient enterostomy and acute intestinal failure. Clin Nutr 2010;29:235‐242. PubMed

Picot D, Layec S, Seynhaeve E, Dussaulx L, Trivin F, Carsin‐Mahe M, et al. Chyme reinfusion in intestinal failure related to temporary double enterostomies and enteroatmospheric fistulas. Nutrients 2020;12:1376. PubMed PMC

Inagaki T, Choi M, Moschetta A, Peng LI, Cummins CL, McDonald JG, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217‐225. PubMed

Cai S‐Y, Ouyang X, Chen Y, Soroka CJ, Wang J, Mennone A, et al. Bile acids initiate cholestatic liver injury by triggering a hepatocyte‐specific inflammatory response. JCI Insight 2017;2:e90780. PubMed PMC

Pereira‐Fantini PM, Lapthorne S, Joyce SA, Dellios NL, Wilson G, Fouhy F, et al. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome–associated liver disease. J Hepatol 2014;61:1115‐1125. PubMed

Xiao Y‐T, Cao YI, Zhou K‐J, Lu L‐N, Cai W. Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure. Sci Rep 2016;6:39264. PubMed PMC

Koelfat KVK, Visschers RGJ, Hodin C, de Waart DR, van Gemert WG, Cleutjens JPM, et al. FXR agonism protects against liver injury in a rat model of intestinal failure–associated liver disease. J Clin Transl Res 2018;3:318‐327. PubMed PMC

Mutanen A, Lohi J, Heikkilä P, Jalanko H, Pakarinen MP. Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure. J Hepatol 2015;62:1391‐1397. PubMed

Koelfat KVK, Huijbers A, Schaap FG, van Kuijk SMJ, Lenicek M, Soeters MR, et al. Low circulating concentrations of citrulline and FGF19 predict chronic cholestasis and poor survival in adult patients with chronic intestinal failure: development of a Model for End‐Stage Intestinal Failure (MESIF risk score). Am J Clin Nutr 2019;109:1620‐1629. PubMed

Walters JRF, Tasleem AM, Omer OS, Brydon WG, Dew T, le Roux CW, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009;7:1189‐1194. PubMed

Hirschfield GM, Chazouillères O, Drenth JP, Thorburn D, Harrison SA, Landis CS, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled phase II trial. J Hepatol 2019;70:483‐493. PubMed

Harrison SA, Rinella ME, Abdelmalek MF, Trotter JF, Paredes AH, Arnold HL, et al. NGM282 for treatment of non‐alcoholic steatohepatitis: a multicentre, randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet 2018;391:1174‐1185. PubMed

Picot D, Layec S, Dussaulx L, Trivin F, Thibault R. Chyme reinfusion in patients with intestinal failure due to temporary double enterostomy: a 15‐year prospective cohort in a referral centre. Clin Nutr 2017;36:593‐600. PubMed

Aziz EF, Javed F, Pratap B, Musat D, Nader A, Pulimi S, et al. Malnutrition as assessed by nutritional risk index is associated with worse outcome in patients admitted with acute decompensated heart failure: an ACAP‐HF data analysis. Heart Int 2011;6:e2. PubMed PMC

Schaap FG, van der Gaag NA, Gouma DJ, Jansen PLM. High expression of the bile salt‐homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009;49:1228‐1235. PubMed

van Eijk HM, Rooyakkers DR, Deutz NE. Rapid routine determination of amino acids in plasma by high‐performance liquid chromatography with a 2–3 microns Spherisorb ODS II column. J Chromatogr 1993;620:143‐148. PubMed

Axelson M, Aly A, Sjovall J. Levels of 7 alpha‐hydroxy‐4‐cholesten‐3‐one in plasma reflect rates of bile acid synthesis in man. FEBS Lett 1988;239:324‐328. PubMed

Koelfat KVK, Plummer MP, Schaap FG, Lenicek M, Jansen PLM, Deane AM, et al. Gallbladder dyskinesia is associated with an impaired postprandial fibroblast growth factor 19 response in critically ill patients. Hepatology 2019;70:308‐318. PubMed

Ruijter JM, Ramakers C, Hoogaars WMH, Karlen Y, Bakker O, van den Hoff MJB, et al. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res 2009;37:e45. PubMed PMC

Eusufzai S, Axelson M, Angelin B, Einarsson K. Serum 7 alpha‐hydroxy‐4‐cholesten‐3‐one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test. Gut 1993;34:698‐701. PubMed PMC

Vergnes L, Lee J, Chin R, Auwerx J, Reue K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab 2013;17:916‐928. PubMed PMC

Sayin S, Wahlström A, Felin J, Jäntti S, Marschall H‐U, Bamberg K, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro‐beta‐muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013;17:225‐235. PubMed

Masubuchi N, Sugihara M, Sugita T, Amano K, Nakano M, Matsuura T, et al. Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: promising diagnostic biomarkers for cholestasis. Chem Biol Interact 2016;255:83‐91. PubMed

Hofmann A. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999;159:2647. PubMed

Crenn P, Coudray–Lucas C, Thuillier F, Cynober L, Messing B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000;119:1496‐1505. PubMed

Hirschfield GM, Chazouilleres O, Drenth JP, Thorburn D, Harrison SA, Landis CS, et al. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled phase II trial. J Hepatol 2019;70:483‐493. PubMed

Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 2014;6:247ra100. PubMed

Mayo MJ, Wigg AJ, Leggett BA, Arnold H, Thompson AJ, Weltman M, et al. NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double‐blind, placebo‐controlled trial. Hepatol Commun 2018;2:1037‐1050. PubMed PMC

Gadaleta RM, Garcia‐Irigoyen O, Cariello M, Scialpi N, Peres C, Vetrano S, et al. Fibroblast growth factor 19 modulates intestinal microbiota and inflammation in presence of farnesoid X receptor. EBioMedicine 2020;54:102719. PubMed PMC

Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen ECL, Renooij W, Murzilli S, et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011;60:463‐472. PubMed

Erlinger S, Dhumeaux D. Mechanisms and control of secretion of bile water and electrolytes. Gastroenterology 1974;66:281‐304. PubMed

Walters JRF, Johnston IM, Nolan JD, Vassie C, Pruzanski ME, Shapiro DA, et al. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol Ther 2015;41:54‐64. PubMed

Wilson SD, Schulte WJ, Meade RC. Longevity studies following total gastrectomy in children with the Zollinger‐Ellison syndrome. Arch Surg 1971;103:108‐115. PubMed

Zaterka S, Grossman MI. The effect of gastrin and histamine on secretion of bile. Gastroenterology 1966;50:500‐505. PubMed

Zhang JH, Nolan JD, Kennie SL, Johnston IM, Dew T, Dixon PH, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol 2013;304:G940‐G948. PubMed PMC

Galman C, Arvidsson I, Angelin B, Rudling M. Monitoring hepatic cholesterol 7alpha‐hydroxylase activity by assay of the stable bile acid intermediate 7alpha‐hydroxy‐4‐cholesten‐3‐one in peripheral blood. J Lipid Res 2003;44:859‐866. PubMed

Microbially conjugated bile salts found in human bile activate the bile salt receptors TGR5 and FXR

New Kids on the Block: Bile Salt Conjugates of Microbial Origin